Dr. Reddy's Laboratories Financial Statements
NYSE: RDYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Dr. Reddy's Laboratories revenue and earnings
In fiscal 2025, Dr. Reddy's Laboratories generated $3.81 billion in revenue, up 13.8% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $663.0 million (-0.7% year over year), for a net margin of 17.4% versus a median of 11.2% in the prior 5 years. Gross margin was 58.5% (down from 58.6%) and operating margin 22.1%.
Diluted earnings per share came in at $0.79, down from $4.01. Over the last 5 fiscal years, RDY's revenue has grown at a 10.5% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Dr. Reddy's Laboratories income statement (annual)
| Fiscal year (USD) | FY 20252025-03-31 | FY 20242024-03-31 | FY 20232023-03-31 | FY 20222022-03-31 | FY 20212021-03-31 | FY 20202020-03-31 | FY 20192019-03-31 | FY 20182018-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.81B | 3.35B | 2.99B | 2.83B | 2.59B | 2.32B | 2.23B | 2.18B |
| Revenue growth (YoY) | +13.76% | +11.97% | +5.87% | +8.94% | +12.00% | +4.09% | +2.02% | — |
| Cost of Revenue | 1.58B | 1.39B | 1.30B | 1.32B | 1.19B | 1.07B | 1.02B | 1.01B |
| Gross Profit | 2.23B | 1.96B | 1.70B | 1.50B | 1.41B | 1.25B | 1.21B | 1.17B |
| Operating Expenses | 1.39B | 1.15B | 1.00B | 1.11B | 1.08B | 1.03B | 904.00M | 989.00M |
| Research & Development | 320.00M | 274.00M | 236.00M | 230.00M | 226.00M | 204.00M | 226.00M | 281.00M |
| Selling, General & Admin | 1.10B | 926.00M | 828.00M | 818.00M | 747.00M | 665.00M | 707.00M | 720.00M |
| Operating Income | 842.00M | 813.00M | 695.00M | 389.00M | 332.00M | 212.00M | 302.00M | 183.00M |
| Interest Expense | 33.00M | 21.00M | 17.00M | 13.00M | 13.00M | 13.00M | 17.00M | 13.00M |
| Pretax Income | 900.00M | 862.00M | 734.00M | 426.00M | 361.00M | 239.00M | 325.00M | 220.00M |
| Income Tax | 229.00M | 194.00M | 186.00M | 115.00M | 125.00M | -19.00M | 53.00M | 70.00M |
| Net Income | 663.00M | 668.00M | 548.00M | 311.00M | 236.00M | 259.00M | 272.00M | 151.00M |
| Net Income growth (YoY) | -0.75% | +21.90% | +76.21% | +31.78% | -8.88% | -4.78% | +80.13% | — |
| EPS (Basic) | 0.79 | 4.02 | 3.30 | 1.87 | 1.42 | 1.56 | 1.64 | 0.91 |
| EPS (Diluted) | 0.79 | 4.01 | 3.30 | 1.87 | 1.52 | 1.56 | 1.64 | 0.91 |
| Shares Outstanding (Basic) | 832.95M | 831.97M | 830.17M | 165.88M | 165.84M | 165.76M | 165.91M | 165.85M |
| Shares Outstanding (Diluted) | 834.18M | 833.54M | 831.94M | 166.34M | 166.32M | 166.08M | 166.19M | 166.19M |
| EBITDA | 1.04B | 991.00M | 849.00M | 545.00M | 507.00M | 377.00M | 478.00M | 363.00M |
| Gross Margin | 58.51% | 58.60% | 56.65% | 53.08% | 54.32% | 53.84% | 54.20% | 53.74% |
| Operating Margin | 22.09% | 24.27% | 23.23% | 13.77% | 12.80% | 9.15% | 13.57% | 8.39% |
| Net Margin | 17.40% | 19.94% | 18.32% | 11.00% | 9.10% | 11.18% | 12.22% | 6.92% |
This table shows 8 annual periods of Dr. Reddy's Laboratories's income statement, from FY 2025 back to FY 2018, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow RDY's reporting calendar. What is a income statement?